tamibarotene has been researched along with sorafenib in 1 studies
Studies (tamibarotene) | Trials (tamibarotene) | Recent Studies (post-2010) (tamibarotene) | Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) |
---|---|---|---|---|---|
198 | 10 | 105 | 6,520 | 730 | 5,251 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ishijima, N; Kanki, K; Shimizu, H; Shiota, G | 1 |
1 other study(ies) available for tamibarotene and sorafenib
Article | Year |
---|---|
Activation of AMP-activated protein kinase by retinoic acid sensitizes hepatocellular carcinoma cells to apoptosis induced by sorafenib.
Topics: Adenosine Triphosphate; AMP-Activated Protein Kinases; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Benzoates; Carcinoma, Hepatocellular; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Glucose Transporter Type 1; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Retinoids; Sorafenib; Tetrahydronaphthalenes; Tretinoin | 2015 |